Tonix Pharmaceuticals Holding Corp. took a giant step toward moving its lead compound, TNX-102, across the goal line by launching the phase III AFFIRM study in patients with fibromyalgia. Read More
Scientists from Cold Spring Harbor Laboratories have adapted the CRISPR/Cas9 gene editing technique in a way that enabled them to comprehensively search for cancer drug targets, by targeting CRISPR to specific protein-coding domains rather than the 5-prime exons of genes. Read More
Sanofi SA is expanding its work with Selecta Biosciences Inc., exercising a multi-million dollar option to license Selecta's antigen-specific immunotherapy platform to underpin a research-stage program targeting the severe gluten allergy celiac disease. Read More
SHANGHAI – Fast on the heels of a major financing round in November, Beigene Co. has raised $97 million in financing, enough cash to continue to aggressively push its deep pipeline of immuno-oncology candidates in the clinic not only in China, but in global trials as well. Read More
LONDON – Restructuring and reshaping of the pharma industry across the globe has resulted in significant fallout in terms of programs, redundant facilities and skills. At the same time there has been significant externalization of R&D. Read More
The success of its breakthrough hepatitis C drug Sovaldi could come back to slap Gilead Sciences Inc., as government agencies like the Department of Veterans Affairs (VA) struggle to pay for the growing demand for the drug. Read More
Cardiome Pharma Corp., of Vancouver, British Columbia, reported that revenue for the first quarter of 2015 was $5.5 million, compared to $7.6 million in the comparable period of 2014. Read More
Atyr Pharma Inc., of San Diego, said it closed its IPO of about 6.2 million shares priced at $14 each, including 804,000 shares purchased to cover overallotments. Gross proceeds totaled $86.3 million. Read More
Mimedx Group Inc., of Marietta, Ga., said the electronic publication of a scientific study in the Journal of Tissue Engineering and Regenerative Medicine, proves the link between the mechanical properties of Collafix fibers and induction of tendon regeneration. Read More
Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., disclosed the start of a phase I trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally administered BCX7353 in healthy volunteers. Read More
